last moon

Sunday, January 3, 2010

Distrusting easy weightbust


If you want to bust your exceeding weight it's better start moving up, training or taking some advice from your own doctor. Taking pills for easy bustweight, according to a research by the EMA, can highly increase the risk on developping heart problems. It seems that Sibutramine, marketed in Great Britain as Reductil and in the USA as Meridia, raising blood pressure, can even lead to heart attack.


Read more



Heart attack and stroke fears over fat-busting wonder pill
By Jo MacfarlaneLast updated at 8:02 AM on 03rd January 2010

Overweight people who have been using Reductil could be more at risk of heart attacks and strokes
A fat-busting pill used by thousands in the UK is being investigated by medicines watchdogs over fears it could cause heart attacks and strokes.
The European Medicines Agency (EMA), which licenses the use of the drug Reductil, is looking at the results of a clinical trial which suggests that its active ingredient, sibutramine, could lead to an increased risk of developing heart problems.
Nearly 330,000 prescriptions for the drug, which tricks the brain into believing the stomach is full, were written out in 2008.
The safety data has come from an international trial of 10,000 patients carried out during the past six years.
Most of those recruited for the Sibutramine Cardiovascular Outcome Trial (SCOUT) were overweight or obese and already had cardiovascular problems.
A heart condition would normally exclude them from taking the drug because it can slightly raise blood pressure.
However, the EMA has said that, as a result of the ‘seriousness’ of the study’s concerns, it is looking at the implications for all patients offered the prescription-only drug and will release its findings later this month.
Until then, it has advised doctors to use Reductil ‘with caution’ and to monitor patients’ blood pressure and heart rate.
The UK’s medicines watchdog, The Medicines and Healthcare Products Regulatory Agency, also confirmed it was reviewing the data.

The agency has recorded 2,094 suspected adverse reactions to Reductil since it was introduced in 2001, and 17 deaths have been linked to the drug. Six of the deaths were caused by heart problems and strokes.
Reductil works by blocking the nerve cells that release and reabsorb the hormone serotonin, a chemical neurotransmitter in the brain that affects moods and appetite.
As the level of serotonin in the body rises, people feel fuller, eat less and, as a result, lose weight.
The drug is recommended for patients who are clinically ‘obese’ – those with a Body Mass Index over 30 – or for anyone with a BMI higher than 27 who has another weight-related health problem.
A spokesman for Abbott Laboratories, which manufacturers Reductil, said: ‘Our ongoing evaluation of the SCOUT study data does not change our medical assessment of sibutramine’s risk/benefit profile when used appropriately in the approved patient population.
'Sibutramine is an important treatment for patients who are obese.Read more: http://www.dailymail.co.uk/health/article-1240147/Heart-attack-stroke-fears-fat-busting-wonder-pill.html#ixzz0bXZ1mFJp

No comments:

Post a Comment